ChromaDex (NASDAQ:CDXC) Rating Lowered to Buy at StockNews.com

ChromaDex (NASDAQ:CDXC) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Monday.

A number of other equities research analysts have also recently weighed in on the stock. Roth Mkm lifted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright boosted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th.

ChromaDex Trading Up 3.4 %

NASDAQ CDXC opened at $7.52 on Monday. The company has a 50-day moving average price of $4.28 and a two-hundred day moving average price of $3.48. ChromaDex has a 52 week low of $1.32 and a 52 week high of $7.67. The stock has a market cap of $574.38 million, a price-to-earnings ratio of 752.75 and a beta of 1.88.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the prior year, the company posted ($0.01) EPS. As a group, equities research analysts expect that ChromaDex will post 0.04 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CDXC. OneDigital Investment Advisors LLC raised its holdings in ChromaDex by 5.5% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock worth $217,000 after buying an additional 3,097 shares during the period. MetLife Investment Management LLC raised its holdings in shares of ChromaDex by 39.3% during the third quarter. MetLife Investment Management LLC now owns 18,114 shares of the company’s stock valued at $66,000 after acquiring an additional 5,115 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of ChromaDex by 75.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company’s stock valued at $72,000 after acquiring an additional 8,485 shares in the last quarter. Miracle Mile Advisors LLC acquired a new position in ChromaDex in the 2nd quarter worth approximately $27,000. Finally, The Manufacturers Life Insurance Company purchased a new position in ChromaDex during the 2nd quarter worth approximately $31,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.